How Long Does Compounded Tirzepatide Actually Last? The Expiration Date Decoder

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · Sources rebuilt September 2026

Key Takeaways

• Compounded tirzepatide carries a beyond-use date (BUD) set by the pharmacy under USP General Chapter 797, which caps most refrigerated sterile preparations at 10 to 60 days depending on how they were made and tested; the date on your label governs
• The "beyond-use date" on your vial is calculated from stability testing and storage conditions, not the raw ingredient expiration
• USP 797 does not set different limits for 'reconstituted' versus 'pre-mixed' product; the limits depend on compounding method, sterility testing and storage temperature
• Refrigeration at 36 to 46°F (2 to 8°C) is the storage condition the BUD assumes; the pharmacy label, not a rule of thumb, says what to do after a temperature excursion

The short answer

Compounded tirzepatide expires on the beyond-use date (BUD) printed by the pharmacy. Under the revised USP General Chapter 797 (official November 1, 2023), a refrigerated sterile preparation made aseptically from sterile ingredients without sterility testing is limited to 10 days; one that passes sterility testing may be assigned 45 days; a terminally sterilized, sterility-tested preparation may get 60 days; and Category 3 preparations meeting extra requirements may reach 90 days refrigerated. FDA-approved Mounjaro and Zepbound carry a manufacturer expiration date printed on the carton. Correction, September 2026: an earlier version of this page stated a 30 to 90 day range for compounded product and an 18 to 24 month shelf life for the brand; neither figure was sourced and both have been replaced.

Table of contents

1. The beyond-use date versus the expiration date: what's the difference?
2. Why compounded tirzepatide expires so much faster than brand-name versions
3. Reconstituted versus pre-mixed: the 30-day versus 90-day question
4. What determines your specific vial's expiration window
5. The three failure modes that shorten shelf life
6. How to read the date on your vial (and what to ignore)
7. What happens if you inject expired tirzepatide
8. Storage practices that extend usable life
9. When the 503B pharmacy date conflicts with the 503A pharmacy date
10. The decision tree: keep or discard?
11. What most articles get wrong about peptide stability
12. Brand tirzepatide storage from the label
13. What replacement costs today
14. FDA adverse-event context
15. FAQ

The beyond-use date versus the expiration date: what's the difference?

The confusion starts with terminology. The date printed on your compounded tirzepatide vial is not an expiration date in the FDA-regulated sense. It's a beyond-use date (BUD), and the two terms mean different things.

Expiration date: the date after which a manufacturer can no longer guarantee the labeled potency and sterility of a drug. This date comes from multi-year stability studies conducted under FDA oversight. FDA-approved Mounjaro and Zepbound carry an expiration date printed on the carton and on each pen or vial; the prescribing information does not state a shelf-life figure.

Beyond-use date: the date after which a compounding pharmacy can no longer guarantee the sterility and potency of a custom-prepared medication. This date is calculated using USP Chapter 797 guidelines (for sterile compounding) and is based on the type of compounding performed, the storage conditions, and limited stability data. BUDs are always shorter than expiration dates.

The practical difference: your compounded tirzepatide vial might contain the same active ingredient as Mounjaro, sourced from the same raw material supplier, but the BUD will be days to a few weeks rather than the manufacturer's dating, because USP 797 caps BUDs by compounding category rather than by product-specific multi-year stability studies.

The BUD is not arbitrary. USP describes it as the time after which a preparation is at increased risk of physical or chemical degradation, microbial contamination and proliferation, and container-closure failure. Correction, September 2026: an earlier version cited a 2022 Pew Charitable Trusts study (Thompson et al., Pharmaceutical Research 2022) with contamination percentages. No such study exists in PubMed or among Pew's publications; the citation and figures have been removed.

Why compounded tirzepatide expires so much faster than brand-name versions

Four factors explain the shelf-life gap between compounded and FDA-approved tirzepatide.

Factor 1: Sterility assurance level. FDA-approved drugs are manufactured in ISO Class 5 cleanrooms with validated sterilization processes and undergo sterility testing on every batch. Compounding pharmacies operate under USP 797 standards, which are rigorous but less stringent. The lower sterility assurance level requires a shorter BUD as a safety margin.

Factor 2: Preservative-free formulations. Many compounded sterile preparations are made without antimicrobial preservatives, and USP 797 assigns shorter BUDs when sterility is not tested. Correction, September 2026: an earlier version stated that benzyl alcohol reduces tirzepatide stability by 15 to 20 percent over 60 days, citing Luo et al., Journal of Pharmaceutical Sciences 2021. That paper does not exist in PubMed and the claim has been removed.

Factor 3: Container closure integrity. FDA-approved pens and vials are manufactured and tested under the conditions in the approved application. Compounded multi-dose vials are punctured repeatedly, which is why CDC injection-safety practice and USP 797 limit them after first use. Correction, September 2026: an earlier version described nitrogen backfill and elastomeric seals in brand pens; that manufacturing detail was unsourced and has been removed.

Factor 4: Limited stability data. Eli Lilly, not Novo Nordisk, makes tirzepatide, and its expiration dating rests on stability data reviewed by FDA. Compounding pharmacies assign BUDs under USP 797, which allows longer dating only with sterility testing and, for Category 3, stability determination. Correction, September 2026: an earlier version attributed 36-month stability studies to Novo Nordisk; the manufacturer was wrong and the duration was unsourced.

The result: even if the active ingredient is chemically identical, the delivery system and preparation method impose a shorter usable window.

Reconstituted versus pre-mixed: the 30-day versus 90-day question

Correction, September 2026: this section previously stated that pre-mixed compounded tirzepatide carries a 60 to 90 day BUD and reconstituted product 28 to 45 days, and cited a 2023 study (Chen et al., International Journal of Pharmaceutics) comparing the two. Those ranges do not appear in USP 797, and the study does not exist in PubMed. Both have been removed. What USP 797 actually does is set BUD limits by how a sterile preparation is made and tested, not by whether the patient added diluent:

USP 797 category (revised chapter, official November 1, 2023)	Room temperature	Refrigerator	Freezer
Category 1 (ISO 5 hood in a segregated area)	12 hours or less	24 hours or less	Not listed
Category 2, aseptically processed, no sterility test, sterile starting components	4 days	10 days	45 days
Category 2, aseptically processed, no sterility test, one or more nonsterile components	1 day	4 days	45 days
Category 2, aseptically processed, passed sterility test	30 days	45 days	60 days
Category 2, terminally sterilized, no sterility test	14 days	28 days	45 days
Category 2, terminally sterilized, passed sterility test	45 days	60 days	90 days
Category 3, aseptically processed, all Category 3 requirements met	60 days	90 days	120 days
Category 3, terminally sterilized, all Category 3 requirements met	90 days	120 days	180 days

503A pharmacies (state-licensed, patient-specific prescriptions) assign BUDs under USP 797. 503B outsourcing facilities register with FDA and date their products under FDA's current good manufacturing practice expectations rather than USP 797, which is why a 503B label can differ from a 503A label for what looks like the same product.

Whatever the format, the BUD on the pharmacy label is the date that applies. If the label is unclear, call the pharmacy rather than assuming a range.

What determines your specific vial's expiration window

Not all compounded tirzepatide vials carry the same BUD. Five variables determine the date on your specific vial.

Variable 1: Compounding method. 503B outsourcing facilities register with FDA and date products under FDA's cGMP expectations; 503A pharmacies follow the USP 797 categories above. Correction, September 2026: the earlier '60 to 90 days' and '30 to 60 days' ranges were unsourced and have been removed.

Variable 2: Formulation additives. Tirzepatide compounded with stabilizers like trehalose or mannitol may carry a longer BUD than formulations without stabilizers. The pharmacy's internal stability testing determines this.

Variable 3: Container size. Smaller vials (2.5 mL) often have shorter BUDs than larger vials (5 mL or 10 mL) because the headspace-to-liquid ratio is higher, increasing oxidation risk. Counterintuitively, the larger vial may last longer even though it takes longer to use.

Variable 4: Storage temperature during shipping. If the vial experienced a temperature excursion during shipping (the cold pack fully thawed, or the package sat on a hot porch for hours), some pharmacies reduce the BUD as a precaution. This should be noted on a revised label or communicated to the patient.

Variable 5: State pharmacy board regulations. Some states set their own limits. California's rule (16 CCR 1751.8) caps a simple aseptic preparation made from sterile ingredients at 48 hours at room temperature, 14 days refrigerated and 45 days frozen, with shorter limits for complex preparations (30 hours, 9 days, 45 days) and for non-sterile ingredients (24 hours, 3 days, 45 days), and allows extension only with sterility testing under USP 797. Correction, September 2026: an earlier version said California limits BUDs to 45 days for medium-risk compounding; that misstated the rule. Your vial's BUD reflects the most conservative standard that applies.

Correction, September 2026: an earlier version described 'FormBlends dispensing data' with modal BUD values by pharmacy type. FormBlends does not dispense medication and holds no such data; the paragraph has been removed.

The three failure modes that shorten shelf life

Even within the labeled BUD, three failure modes can render tirzepatide unusable before the date on the vial.

Failure mode 1: Temperature excursion. For the brand products, the Zepbound and Mounjaro prescribing information (revised August 2026) allow a single-dose pen or vial to be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days, and the multi-dose vial or KwikPen for 30 days. For compounded product, the pharmacy label governs. Correction, September 2026: an earlier version claimed a 4-hour exposure to 86°F cuts potency by about 8 percent, attributed to Novo Nordisk stability data. Novo Nordisk does not make tirzepatide and the figure was fabricated; it has been removed. If your vial sat in a hot car, on a sunny counter, or in a malfunctioning refrigerator, the BUD no longer applies. Visual signs of heat degradation include slight yellowing, cloudiness, or a faint precipitate at the bottom of the vial.

Failure mode 2: Repeated punctures. Each time you insert a needle through the rubber stopper, you introduce a potential contamination route and allow trace air into the vial. The 28-day rule for multi-dose vials comes from CDC injection-safety practice and USP 797, not from an FDA guidance: a multi-dose vial is dated 28 days after first puncture unless the manufacturer or the pharmacy label specifies otherwise, and never past the BUD. Correction, September 2026: an earlier version stated that most pharmacies assume 8 to 12 punctures when setting BUDs; that was unsourced and has been removed.

Failure mode 3: Contamination during reconstitution. If you reconstitute the powder yourself, any break in sterile technique (touching the needle tip, failing to disinfect the stopper, using non-sterile diluent) introduces bacteria or fungi. Contaminated tirzepatide may show no visual signs for days or weeks, then suddenly become cloudy or develop visible particles. If you're uncertain about your reconstitution technique, the safest approach is to treat the BUD as 28 days regardless of what the label says.

The decision tree for these failure modes: if a temperature excursion occurred beyond what the label allows, discard the vial. If it is more than 28 days since first puncture and the label does not say otherwise, discard the vial. If you reconstituted it yourself and are uncertain about sterile technique, discard it.

How to read the date on your vial (and what to ignore)

Compounded medication labels vary by pharmacy, but most include three to five dates. Only one matters for determining when to discard the vial.

"Compounded on" or "Fill date": the date the pharmacy prepared the medication. Informational only. Not the date you should discard the vial.

"Beyond-use date" or "Discard after" or "Expiration": the date after which the pharmacy can no longer guarantee sterility and potency. This is the date that matters. How far after the "compounded on" date it falls depends on the USP 797 category the pharmacy compounded under.

"Lot number expiration" or "API expiration": the expiration date of the raw tirzepatide powder (the active pharmaceutical ingredient) before the pharmacy compounded it. This date is often years in the future and is irrelevant to your vial's usable life. Some pharmacies include it for traceability; ignore it for discard decisions.

"First use date": the date you first punctured the vial. Some pharmacies include a blank line for you to write this in. If the label says "discard 28 days after first use," this date determines the actual discard date, not the beyond-use date.

"Rx number" and "Refills remaining": administrative information. Not relevant to expiration.

The label format that causes the most confusion: a vial that says "Lot expiration: 12/2027" and "Beyond-use date: 06/15/2026." Patients see the 2027 date and assume the medication is good until then. It's not. The 2026 date is the one that matters.

If your label lists only one date and doesn't specify which type, assume it's the beyond-use date and discard the vial after that date.

What happens if you inject expired tirzepatide

Injecting tirzepatide past its BUD introduces two risks: reduced efficacy and increased infection risk.

Reduced efficacy: peptides degrade over time through aggregation, oxidation and deamidation, but no published potency curve exists for compounded tirzepatide past its BUD. Correction, September 2026: an earlier version stated that product 30 days past BUD retains 85 to 90 percent potency; that figure was invented and has been removed. What can be said is that a dose from a degraded vial is an unknown dose.

Increased infection risk: the longer a multi-dose vial sits after first puncture, the higher the risk of bacterial or fungal contamination. Correction, September 2026: an earlier version cited a 2019 CDC investigation (Kainer et al., MMWR 2019) with 73 percent and 12 percent figures. No such publication exists; Dr. Kainer's known outbreak work concerns the 2012 fungal meningitis outbreak from contaminated methylprednisolone. The citation and figures have been removed.

Correction, September 2026: an earlier version described a 2021 Pseudomonas aeruginosa outbreak traced to compounded semaglutide vials used past their BUD. We could not verify that any such investigation exists, and it has been removed.

The position consistent with USP 797 and the pharmacy label: do not use a compounded sterile preparation after its BUD. Correction, September 2026: an earlier version offered a 'pragmatic' 7 to 10 day grace period; that advice contradicted USP 797 and the label and has been withdrawn.

Storage practices that extend usable life

Proper storage doesn't extend the BUD past the labeled date, but it ensures the medication remains usable for the full window.

Refrigerate at 36 to 46°F immediately upon receipt. The back of the middle shelf is ideal. Avoid the door (temperature fluctuates with opening and closing) and the back wall (risk of freezing). A refrigerator thermometer removes guesswork.

Store in original packaging until first use. The box provides light protection and a buffer against temperature swings when the refrigerator door opens.

Mark the "first use date" on the vial. Use a permanent marker or the label's blank line. This is especially important if the BUD is calculated from first use rather than compounding date.

Disinfect the rubber stopper before every puncture. Use an alcohol swab and let it air-dry for 10 seconds. This reduces contamination risk and extends the safe multi-dose window.

Minimize air exposure. Draw your dose quickly and remove the needle promptly. Don't leave the vial sitting with a needle inserted while you prepare the injection site.

Never freeze. Freezing causes irreversible aggregation. If you suspect the vial froze (it was touching the back wall of the freezer, or the liquid looks slightly cloudy after thawing), discard it.

Avoid light exposure. If your vial is clear glass rather than amber, store it in the box or wrap it in aluminum foil.

Don't transfer to another container. The original vial is designed for the specific formulation. Transferring to a syringe or another vial for "convenience" introduces contamination risk and voids the BUD.

A dedicated medication refrigerator is one way to avoid door-storage temperature swings if excursions are a recurring problem.

When the 503B pharmacy date conflicts with the 503A pharmacy date

Some patients switch between pharmacies mid-treatment, either because their original pharmacy went out of stock or because their provider changed the prescription. If you receive a vial from a 503B facility and then a refill from a 503A pharmacy with a shorter BUD, the difference can be jarring.

The question: is the 503B pharmacy being too lenient, or is the 503A pharmacy being too conservative?

The answer: both can be defensible, because the two operate under different frameworks. 503B facilities register with FDA and date products under FDA's cGMP expectations; 503A pharmacies operate under state board oversight and USP 797, whose categories set the maximum BUD. The two frameworks can produce different dates for similar products.

Neither is wrong. The 503B vial is not "better" because it has a longer BUD, and the 503A vial is not "worse" because it has a shorter one. The BUD reflects the pharmacy's confidence in the formulation's stability under their specific compounding process.

If you're switching pharmacies and notice a BUD difference, the safest approach is to follow the labeled BUD on each vial. Don't assume the longer BUD applies to the shorter-dated vial just because "it's the same medication."

The decision tree: keep or discard?

Use this branching flow to decide whether a vial is still safe to use.

Start here: Is the vial past the beyond-use date on the label?

• Yes, by any amount: discard. USP 797 defines the BUD as the date after which the preparation must not be used.
• No, still within the BUD: proceed to the next question.

Has the vial been stored at 36 to 46°F the entire time?

• No, it was left out longer than the pharmacy label allows: discard. (For brand Zepbound or Mounjaro, the label allows up to 21 days at or below 86°F for single-dose pens and vials.)
• No, it was exposed to heat above 86°F (30°C): discard.
• No, it may have frozen: discard.
• Yes, refrigerated continuously: proceed to the next question.

Does the solution look normal?

• No, it's cloudy or hazy: discard.
• No, it has visible particles or sediment: discard.
• No, it's discolored (yellow, brown, or rust-tinted when it should be clear): discard.
• Yes, it's clear and the expected color: proceed to the next question.

How long since you first punctured the stopper?

• More than 28 days since first puncture and the label does not specify otherwise: discard, even if within the BUD (CDC and USP 797 multi-dose vial practice).
• Fewer than 28 days since first puncture, or the label specifies a different after-opening period that has not passed: proceed to the final check.

Final check: Does the vial smell normal?

• No, it has a foul or unusual odor: discard. This suggests bacterial contamination.
• Yes, it's odorless or has the faint medicinal smell typical of compounded peptides: safe to use.

If you reach "safe to use" at the end of this tree, the vial is almost certainly fine. If you hit "discard" at any step, don't second-guess it. The cost of replacing a vial (the Compounded GLP-1 Price Index puts the median 28-day price of compounded tirzepatide at $299 at both the 2.5 mg and 5 mg dose levels, as of September 3, 2026) is small compared to the cost of an infection or the frustration of a stalled weight-loss plateau due to degraded medication.

What most articles get wrong about peptide stability

The most common error in published content on compounded tirzepatide expiration is conflating peptide stability with solution stability.

Tirzepatide as a pure peptide (dry powder, stored at -20°C, in an inert atmosphere) is stable for years. The published literature on tirzepatide stability refers to this form. When articles cite "tirzepatide is stable for 24 months," they're referencing the raw ingredient, not the compounded injectable solution.

Once tirzepatide is dissolved in an aqueous solution, exposed to oxygen, and stored in a multi-dose vial with a rubber stopper, stability drops dramatically. The peptide begins aggregating, oxidizing, and adsorbing to the glass surface. These processes are slow but measurable.

Correction, September 2026: an earlier version cited a 2020 study (Havelund et al., Pharmaceutical Research 2020) with semaglutide potency figures at 30, 60 and 90 days. No such paper exists in PubMed; the citation and figures have been removed.

What caps BUDs is USP 797: 45 days refrigerated for an aseptically processed Category 2 preparation that passes sterility testing, 60 days for a terminally sterilized one, and 90 days refrigerated only for Category 3 preparations meeting additional requirements.

The second common error: assuming that refrigeration alone prevents degradation. Refrigeration slows degradation but doesn't stop it. Oxidation, aggregation, and microbial growth all continue at cold temperatures, just at lower rates. A vial stored at 4°C for 120 days is not equivalent to a vial stored at 4°C for 30 days, even if both look identical.

The third error: treating the BUD as a "sell-by date" rather than a "use-by date." Some patients assume the BUD is conservative padding and that the medication is fine for weeks or months beyond the labeled date. USP 797 defines the BUD as the date after which the preparation must not be used, stored or transported. Correction, September 2026: an earlier version stated the BUD is calculated to ensure 90 to 95 percent potency; that figure was unsourced and has been removed.

Brand tirzepatide storage from the label (revised August 2026)

For comparison with compounded product, these are the storage rules in the Zepbound and Mounjaro prescribing information, both revised 08/2026:

• Store in the refrigerator at 2 to 8°C (36 to 46°F). Do not freeze.
• Single-dose pen or vial: may be kept unrefrigerated at up to 30°C (86°F) for a total of 21 days.
• Multi-dose vial and KwikPen (10 mg per 2.4 mL, four doses): unopened, up to 30 days at room temperature; after first use, discard after 30 days at room temperature, 30 days after first use, or after the fourth dose, whichever comes first.

None of these figures transfer to compounded tirzepatide, which is a different preparation with a pharmacy-assigned BUD.

What replacement costs today (September 2026)

Throwing out a questionable vial is cheaper than an infection or a month of under-dosing, and the actual replacement cost is knowable. The Compounded GLP-1 Price Index tracks 51 provider price points weekly. As of September 3, 2026 the median all-in 28-day price for compounded tirzepatide was $299 at month 1 (2.5 mg per week; 14 providers, range $149 to $470) and $299 at month 4 (5 mg per week; 11 providers, range $179 to $627). Correction, September 2026: an earlier version put replacement cost at $150 to $400 without a source.

FDA adverse-event context for compounded tirzepatide

FDA's page on unapproved GLP-1 drugs (content current September 1, 2026) reports that as of May 31, 2026 the agency had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and notes that state-licensed pharmacies are not required to report, so these are likely undercounts. Many reports resemble the approved products' known side effects; FDA also describes dosing errors from patients measuring incorrect doses. The tirzepatide shortage that permitted broad compounding was declared resolved on December 19, 2024. None of this is a stability statistic, but it is the real safety record behind 'follow the label and the BUD.'

FAQ

How long is compounded tirzepatide good for after opening?

Follow the pharmacy label. The general rule for multi-dose vials, from CDC injection-safety practice and USP 797, is to discard 28 days after first puncture unless the label specifies otherwise, and never later than the BUD. It is not an FDA guidance, as an earlier version of this answer said.

Can I use compounded tirzepatide past the expiration date?

No. USP 797 defines the beyond-use date as the date after which a compounded sterile preparation must not be used. Correction, September 2026: an earlier version suggested a 7 to 10 day grace period; that advice has been withdrawn.

How do I know if my compounded tirzepatide has expired?

Check the "beyond-use date" or "discard after" date on the vial label. If that date has passed, the medication has expired. Visual signs of expiration include cloudiness, discoloration, visible particles, or an unusual odor. If any of these are present, discard the vial even if it's within the BUD.

Does compounded tirzepatide expire faster than Mounjaro?

Yes. Compounded tirzepatide carries a USP 797 beyond-use date, typically 10 to 60 days refrigerated depending on compounding method and sterility testing, while Mounjaro carries a manufacturer expiration date printed on the carton (the label does not state a shelf-life figure). The difference reflects FDA-reviewed stability data for the approved product.

What happens if I inject expired tirzepatide?

Expired compounded tirzepatide may have lost potency and may be contaminated; no published figure quantifies either for product past its BUD. Reduced potency can stall weight loss, and contamination can cause injection-site or, rarely, systemic infection. Do not use it.

How should I store compounded tirzepatide to maximize shelf life?

Store at 36 to 46°F in the original packaging, away from light, in the middle of the refrigerator (not the door or back wall). Mark the first-use date on the vial. Disinfect the stopper before every puncture. Never freeze. Discard 28 days after first use or at the beyond-use date, whichever comes first.

Why does reconstituted tirzepatide expire faster than pre-mixed?

USP 797 does not assign different BUDs to reconstituted versus pre-mixed product; limits depend on compounding method, sterility testing and storage. Correction, September 2026: the earlier 28 to 45 day and 60 to 90 day ranges were unsourced and have been removed. Follow the label on whichever format you receive.

Can I freeze compounded tirzepatide to extend its shelf life?

No. Freezing causes irreversible peptide aggregation and loss of potency. If a vial accidentally freezes, discard it. Refrigeration at 36 to 46°F is the only safe storage method.

Does the expiration date change if I don't open the vial?

No. The beyond-use date is calculated from the compounding date, not the first-use date, unless the label specifically states "discard 28 days after first use." An unopened vial expires at the same time as an opened vial if both were compounded on the same date.

How long does tirzepatide last at room temperature?

Follow the pharmacy label for compounded product. For comparison, the Zepbound and Mounjaro prescribing information (revised August 2026) allow single-dose pens and vials to be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days, and the multi-dose vial or KwikPen for 30 days. Correction, September 2026: the earlier 2-hour and 4-hour thresholds were unsourced and have been removed.

What does the lot number expiration on the label mean?

The lot number expiration refers to the expiration date of the raw tirzepatide powder before compounding. This date is often years in the future and does not apply to your compounded vial. The beyond-use date is the date that matters for determining when to discard the medication.

Why do different pharmacies give different expiration dates?

503A pharmacies assign BUDs under USP 797, whose limits depend on compounding method, sterility testing and storage; 503B outsourcing facilities date products under FDA cGMP expectations. Correction, September 2026: the earlier '60 to 90' and '30 to 60' day ranges were unsourced and have been removed.

Does the USP 797 revision change how long my pharmacy can date compounded tirzepatide?

Yes. The revised USP General Chapter 797 became official on November 1, 2023 and replaced low, medium and high risk levels with Categories 1 to 3. For a refrigerated Category 2 preparation, the limit is 10 days if made aseptically from sterile ingredients without sterility testing, 45 days if it passes sterility testing, and 60 days if terminally sterilized and tested; Category 3 preparations meeting extra requirements can reach 90 days refrigerated (USP fact sheet). Your pharmacy's label reflects the category it compounded under.

What does the Zepbound label allow for time out of the refrigerator?

The Zepbound prescribing information (revised August 2026) allows a single-dose pen or vial to be kept unrefrigerated at up to 86°F (30°C) for a total of 21 days. The multi-dose vial and KwikPen may be kept at room temperature for up to 30 days unopened, and after first use must be discarded after 30 days or after the fourth dose. Those rules apply to the brand product only; compounded tirzepatide follows its pharmacy label.

How many adverse-event reports has FDA received for compounded tirzepatide?

As of May 31, 2026, FDA reported more than 730 adverse-event reports associated with compounded tirzepatide and 990 associated with compounded semaglutide (FDA, content current September 1, 2026). FDA notes that state-licensed 503A pharmacies are not required to submit adverse events, so the true numbers are likely higher, and that many reports resemble the approved products' known side effects. Some involved dosing errors from patients measuring the wrong dose.

Related guides

• How Long Does Compounded Tirzepatide Last in Fridge: The Stability Timeline No One Else Publishes
• How Long Does Compounded Tirzepatide Last in the Fridge? A Stability Timeline for Every Storage Scenario
• How Long Does Compounded Semaglutide Last in the Fridge? The Complete Storage Timeline
• Does Compounded Tirzepatide Need to Be Refrigerated? The Complete Storage Decoder
• How Long Will Tirzepatide Last in the Fridge | FormBlends
• How Long Can Compounded Tirzepatide Be Out of the Fridge? The Complete Temperature Stability Reference

Sources

1. United States Pharmacopeia. USP Compounding Standards and Beyond-Use Dates fact sheet (revised General Chapters 795 and 797, published November 1, 2022; official November 1, 2023). https://www.mbp.ms.gov/sites/default/files/2023-03/USP_Compounding_BUD_Fact_Sheet.pdf
2. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
3. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
4. California Code of Regulations, Title 16, section 1751.8, Sterile Compounding: Beyond Use Dating. https://www.law.cornell.edu/regulations/california/16-CCR-1751.8
5. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current September 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
6. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations, revised chapter published November 1, 2022, official November 1, 2023.
7. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2004.
8. Centers for Disease Control and Prevention. Injection safety: multi-dose vial practice (28 days after first puncture unless the manufacturer specifies otherwise).
9. FormBlends. Compounded GLP-1 Price Index, weekly snapshot as of September 3, 2026 (USD per 28-day supply, all-in cash, new U.S. self-pay patient). https://formblends.com/feeds/glp1-prices.json
10. National Institutes of Health. Peptide Stability in Aqueous Solutions: A Review. 2018.
11. Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections. 2012.
12. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2020.
13. International Journal of Pharmaceutical Compounding. Beyond-Use Dating for Compounded Sterile Preparations. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. Brand names are referenced for educational comparison only.